Phase 3
Completed N=454
Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)
Source: ClinicalTrials.gov NCT00928187 ↗Enrolled (actual)
454
Serious AEs
12.0%
Results posted
Nov 2016
Primary outcomePrimary: Number of Patients With Plasma HIV RNA < 50 Copies/mL — 105; 92; 97 participants
◆ Published Evidence
Emerging
7citations · ~1 / year
Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa.
Summary
Since the first line antiretroviral (ARV) treatment is now largely accessible in the Sub-Saharian Africa countries, documentation of virological failure, drug resistance patterns and second line treatment evaluation are still to be consolidated in settings where viral load monitoring is not available and non-B HIV subtype is predominant.
This trial aims at evaluating the efficacy and tolerance of 3 different second line treatment strategies: two recommended by WHO combine two non-nucleoside reverse transcriptase inhibitor associated with a ritonavir boosted protease inhibitor (emtricitabine-tenofovir-lopinavir/ritonavir and abacavir-didanosine-lopinavir/ritonavir); the third strategy combines emtricitabine-tenofovir-darunavir/ritonavir and is not yet evaluated in Sub-Saharian Africa. Darunavir has a potentially superior antiviral efficacy, a better tolerance and its single daily administration may facilitate treatment adherence.
Linked Publications
-
Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients With Plasma HIV RNA < 50 Copies/mL |
105; 92; 97 | — |
| SECONDARY Number of Patients With WHO Stage 3 and 4 HIV Related Events |
17; 23; 30 | — |
| SECONDARY Patients With Plasma HIV RNA < 200 Copies/ml |
130; 118; 127 | — |
| SECONDARY Gain in CD4 Cells Between Baseline and W48 |
133; 136; 115 | — |
| SECONDARY Number of Patients Discontinuing Study Treatment |
0; 4; 1 | — |
| SECONDARY Tolerance: Gastrointestinal Complains |
50; 48; 26 | 0.001 sig |
| SECONDARY Tolerance: Neuropathies (Grade 1 to 4) |
5; 11; 8 | 0.26 |
| SECONDARY Tolerance: Equal or Superior to a 25% Reduction in eGFR (Glomerular Filtration Rate) |
28; 14; 19 | 0.13 |
| SECONDARY Adherence |
50; 54; 67; 89; 72; 78 | — |
| SECONDARY Number of Patients With Resistance Mutations |
0; 0; 0 | — |
| SECONDARY Development of Metabolic Syndrome |
12; 21; 9 | — |
| SECONDARY Number of Patients With HIV Plasma Viral Load < 50 Copies/ml |
90; 81; 97 | — |
| SECONDARY Number of Patients With HIV Plasma Viral Load < 200 Copies/ml |
127; 117; 129 | — |
Eligibility Criteria
Inclusion Criteria
- Patient over the age of 18 years at pre-inclusion and monitored under outpatient conditions
- Documented HIV-1 infection regardless of clinical stage and CD4 lymphocyte count
- Patient with treatment failure after first-line antiretroviral treatment with a combination including a non-nucleoside reverse transcriptase inhibitor and two nucleoside reverse transcriptase inhibitors, failure being defined as 2 measurements (at 1 month interval) of plasma HIV RNA levels > 1000 copies/ml after at least 6 months of uninterrupted treatment
- Adherence (> 80%) to first- line antiretroviral treatment (questionnaire) at pre inclusion
- Patient agrees not to take any concomitant medication during the trial without informing the investigator
- Informed consent signed no later than D-15
- For women in childbearing age: negative pregnancy test at inclusion, with no plan of pregnancy in the coming 12 months and agreeing to use mechanical contraception (with or without hormonal contraception) during the study
Exclusion Criteria
- Infection with HIV-2 or HIV-1 groups O or N or HIV1+2
- Deficiency of the patient, making it difficult, if not impossible, for him/her to take part in the trial or understand the information provided to him/her
- Participation in any other clinical trial
- Presence of an uncontrolled, ongoing opportunistic infection or of any severe or progressive disease
- First-line treatment with a protease inhibitor, abacavir, tenofovir or ddI
- Ongoing treatment with rifampicin
- Severe hepatic insufficiency (TP 3 x ULN
- Creatinine clearance calculated by Cockcroft formula < 50 ml/min
- Hb ≤ 8 g/dl
- Platelets < 50,000 cells/mm3
- Neutrophiles < 500 cells/ mm3
- Use of drugs prohibited in the context of this trial (drugs contraindicated by the SCP of the trial drugs) - in the event of tuberculosis or malaria during the trial, a list of authorized medicines and, if necessary, a dose adjustment of the antiretroviral medication will be provided
- Pregnancy or lactation
Data sourced from ClinicalTrials.gov (NCT00928187) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.